发布求助
文献互助 智能选刊 最新文献

Blood Cancer Discovery最新文献

筛选
英文 中文
Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.
IF 11.5
Blood Cancer Discovery Pub Date : 2025-03-04 DOI: 10.1158/2643-3230.BCD-24-0153
Christopher R Flowers, Rachel W Anantha, Veronica Leautaud, Pinkal Desai, Chancellor E Donald, Michelle A T Hildebrandt, Jean L Koff, Rulla M Tamimi, Wendy Cozen, Chijioke Nze, Ari M Melnick
{"title":"Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.","authors":"Christopher R Flowers, Rachel W Anantha, Veronica Leautaud, Pinkal Desai, Chancellor E Donald, Michelle A T Hildebrandt, Jean L Koff, Rulla M Tamimi, Wendy Cozen, Chijioke Nze, Ari M Melnick","doi":"10.1158/2643-3230.BCD-24-0153","DOIUrl":"10.1158/2643-3230.BCD-24-0153","url":null,"abstract":"<p><strong>Significance: </strong>This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need to enhance collaborative infrastructure to engage laboratory researchers, epidemiologists, data scientists, clinicians, patients, community leaders, and policymakers; patient-level support services; outreach, education, and navigation for patients at the community level; recruitment and retention of underrepresented groups in the healthcare and research workforce; and funding for these efforts.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"79-93"},"PeriodicalIF":11.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development. 白血病发生中克隆进化、分化层次和个体发生的十字路口。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-03-04 DOI: 10.1158/2643-3230.BCD-24-0235
Christopher M Sturgeon, Elvin Wagenblast, Franco Izzo, Eirini P Papapetrou
{"title":"The Crossroads of Clonal Evolution, Differentiation Hierarchy, and Ontogeny in Leukemia Development.","authors":"Christopher M Sturgeon, Elvin Wagenblast, Franco Izzo, Eirini P Papapetrou","doi":"10.1158/2643-3230.BCD-24-0235","DOIUrl":"10.1158/2643-3230.BCD-24-0235","url":null,"abstract":"<p><strong>Significance: </strong>In recent years, remarkable technological advances have illuminated aspects of the pathogenesis of myeloid malignancies-yet outcomes for patients with these devastating diseases have not significantly improved. We posit that a synthesized view of the three dimensions through which hematopoietic cells transit during their healthy and diseased life-clonal evolution, stem cell hierarchy, and ontogeny-promises high yields in new insights into disease pathogenesis and new therapeutic avenues.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"94-109"},"PeriodicalIF":11.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142801596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma. 大 B 细胞淋巴瘤 CAR-T 细胞产品的免疫重建动态及其对疗效的影响
IF 11.5
Blood Cancer Discovery Pub Date : 2025-03-04 DOI: 10.1158/2643-3230.BCD-24-0163
Danny Luan, Susan DeWolf, Teng Fei, Sandeep Raj, Gunjan L Shah, Caleb A Lareau, Mohammad Alhomoud, Gilles Salles, Alfredo Rivas-Delgado, Kai Rejeski, Jae H Park, Efrat Luttwak, Alejandro Luna de Abia, Magdalena Corona, Evangelos Ntrivalas, Giulio Cassanello, Marina Gomez-Llobell, Allison Parascondola, Michael Scordo, Katharine C Hsu, M Lia Palomba, Miguel-Angel Perales, Roni Shouval
{"title":"Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.","authors":"Danny Luan, Susan DeWolf, Teng Fei, Sandeep Raj, Gunjan L Shah, Caleb A Lareau, Mohammad Alhomoud, Gilles Salles, Alfredo Rivas-Delgado, Kai Rejeski, Jae H Park, Efrat Luttwak, Alejandro Luna de Abia, Magdalena Corona, Evangelos Ntrivalas, Giulio Cassanello, Marina Gomez-Llobell, Allison Parascondola, Michael Scordo, Katharine C Hsu, M Lia Palomba, Miguel-Angel Perales, Roni Shouval","doi":"10.1158/2643-3230.BCD-24-0163","DOIUrl":"10.1158/2643-3230.BCD-24-0163","url":null,"abstract":"<p><strong>Significance: </strong>This study reveals differences in IR patterns after CAR-T therapy in patients with large B-cell lymphoma, with early NK cell recovery emerging as a key predictor of survival. These findings provide potential future avenues of research for improving patient outcomes and tailoring post-therapy management strategies to mitigate relapse risk.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"119-130"},"PeriodicalIF":11.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation. 儿童造血细胞移植长期存活患者克隆造血能力增加。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-03-04 DOI: 10.1158/2643-3230.BCD-24-0136
Konradin F Müskens, Nienke Wieringa, Maaike G J M van Bergen, Joëll E Bense, Brigit M Te Pas, Anne P J de Pagter, Arjan C Lankester, Marc B Bierings, Donna S Neuberg, Saskia Haitjema, Leontien C M Kremer, Gerwin A Huls, Stefan Nierkens, Joop H Jansen, Caroline A Lindemans, Aniek O de Graaf, Mirjam E Belderbos
{"title":"Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation.","authors":"Konradin F Müskens, Nienke Wieringa, Maaike G J M van Bergen, Joëll E Bense, Brigit M Te Pas, Anne P J de Pagter, Arjan C Lankester, Marc B Bierings, Donna S Neuberg, Saskia Haitjema, Leontien C M Kremer, Gerwin A Huls, Stefan Nierkens, Joop H Jansen, Caroline A Lindemans, Aniek O de Graaf, Mirjam E Belderbos","doi":"10.1158/2643-3230.BCD-24-0136","DOIUrl":"10.1158/2643-3230.BCD-24-0136","url":null,"abstract":"<p><strong>Significance: </strong>As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"110-118"},"PeriodicalIF":11.5,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma. 肿瘤内和患者间异质性模型解释了淋巴瘤根治性联合疗法的临床试验。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-24 DOI: 10.1158/2643-3230.BCD-24-0230
Amy E Pomeroy, Adam C Palmer
{"title":"A model of intra-tumor and inter-patient heterogeneity explains clinical trials of curative combination therapy for lymphoma.","authors":"Amy E Pomeroy, Adam C Palmer","doi":"10.1158/2643-3230.BCD-24-0230","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0230","url":null,"abstract":"<p><p>Models of tumor drug response have illuminated important concepts in oncology, but there remains a need for theory that combines intra-tumor and inter-patient heterogeneity to explain patient outcomes, especially for curative treatments. We present a mathematical model of multi-drug therapy that describes both cell-to-cell and patient-to-patient heterogeneity as distributions of drug sensitivity, and apply it to simulate curative combination therapies for Diffuse Large B-Cell Lymphoma (DLBCL). Simulated trials reproduced Progression-Free Survival and changes in circulating tumor DNA observed under standard therapy, and accurately predicted success or failure of nine randomized trials of first-line combinations based on drugs' efficacies in relapsed/refractory DLBCL. Finally, we used the model to explore how drug synergies, biomarkers, and subtype-specific endpoints could improve the chance of success of targeted combination therapies. This study offers a quantitative model of curative drug combinations and suggests that predictive simulations could aid the design of new regimens with curative intent.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity. SOCS1 可保护急性髓性白血病免受异体 T 细胞介导的细胞毒性的影响。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-10 DOI: 10.1158/2643-3230.BCD-24-0140
Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Neil MacLean, Jayakumar Vadakekolathu, Mark D Minden, Aaron D Schimmer, JongBok Lee, Li Zhang
{"title":"SOCS1 protects acute myeloid leukemia against allogeneic T cell-mediated cytotoxicity.","authors":"Enoch Tin, Sergio Rutella, Ismat Khatri, Yoosu Na, Yongran Yan, Neil MacLean, Jayakumar Vadakekolathu, Mark D Minden, Aaron D Schimmer, JongBok Lee, Li Zhang","doi":"10.1158/2643-3230.BCD-24-0140","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0140","url":null,"abstract":"<p><p>Despite the curative potential of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML), its efficacy is limited by intrinsic resistance of cancer cells to donor-derived T-cell cytotoxicity. Using a genome-wide CRISPR screen, we identified the SOCS1-JAK1-STAT1 pathway as a mediator of AML susceptibility to T cells. SOCS1 knockdown in AML cells sensitized them to killing by allogeneic T cells, whereas SOCS1 overexpression in AML cells induced resistance to T-cell anti-leukemic activity. Mechanistically, SOCS1 protected AML cells from T-cell killing by antagonizing IFNγ-JAK1-induced ICAM-1 expression. Furthermore, primary AML cells with lower SOCS1 expression correlated with better overall survival in patients, especially those with a lower exhausted CD8+ T-cell score. Thus, this study reveals SOCS1 and its downstream mediators as a potential targetable pathway to enhance T cell-based immunotherapy for AML.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study.
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-06 DOI: 10.1158/2643-3230.BCD-24-0156
Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang
{"title":"High-dose methotrexate, ibrutinib, and temozolomide in the treatment of newly diagnosed primary CNS lymphoma: a multicenter, prospective phase-II study.","authors":"Yan Gao, Liqin Ping, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Mingyao Lai, Linbo Cai, Bing Bai, Cheng Huang, Haoqing Chen, Xiaoyu Hong, Xiaoxiao Wang, Huiqiang Huang","doi":"10.1158/2643-3230.BCD-24-0156","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0156","url":null,"abstract":"<p><p>Genetic alterations of chronic active B-cell receptor signaling often occur in primary central nervous system lymphoma (PCNSL). We conducted a phase-II trial of high-dose methotrexate plus ibrutinib and temozolomide (MIT) in the treatment of newly diagnosed PCNSL. A total of 35 patients were enrolled, with 33 patients included in the analysis. The best overall response rate was 93.9% and complete response rate was 72.7% for induction therapy. The 2-year progression-free survival (PFS) and overall survival were 57.6% (95%CI: 49.0-66.2) and 84.8% (95%CI: 78.6-91.0). The incidence of grade ≧ 3 adverse events was 27.3% (10/33). Mutations in PIM1, MYD88, BTG2, and CD79B were most frequent among 475 genes tested by targeted sequencing of tumor and CSF samples at baseline. The consistency of ctDNA clearance from CSF/plasma and complete response on imaging were observed. Patients with clearance of ctDNA from CSF after two cycles achieved longer PFS (p = 0.044).</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.
IF 11.5
Blood Cancer Discovery Pub Date : 2025-02-06 DOI: 10.1158/2643-3230.BCD-24-0178
Nora Liebers, Ariane Boumendil, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Baermann, Yasmina Serroukh, Didier Blaise, Dietrich Wilhelm Beelen, Carlos Solano, Maija Itälä-Remes, Tom van Meerten, Goda Choi, Susanne A C Schmidt, Nicolaus Kröger, Jenny Byrne, Jean-Jacques Tudesq, Anna Ossami Saidy, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Sureda, Bertram Glass, Sascha Dietrich
{"title":"Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma.","authors":"Nora Liebers, Ariane Boumendil, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Baermann, Yasmina Serroukh, Didier Blaise, Dietrich Wilhelm Beelen, Carlos Solano, Maija Itälä-Remes, Tom van Meerten, Goda Choi, Susanne A C Schmidt, Nicolaus Kröger, Jenny Byrne, Jean-Jacques Tudesq, Anna Ossami Saidy, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Sureda, Bertram Glass, Sascha Dietrich","doi":"10.1158/2643-3230.BCD-24-0178","DOIUrl":"https://doi.org/10.1158/2643-3230.BCD-24-0178","url":null,"abstract":"<p><p>Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia. 基于 Venetoclax 的急性髓性白血病联合疗法
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0171
Hannah Goulart, Hagop Kantarjian, Naveen Pemmaraju, Naval Daver, Courtney D DiNardo, Caitlin R Rausch, Farhad Ravandi, Tapan M Kadia
{"title":"Venetoclax-Based Combination Regimens in Acute Myeloid Leukemia.","authors":"Hannah Goulart, Hagop Kantarjian, Naveen Pemmaraju, Naval Daver, Courtney D DiNardo, Caitlin R Rausch, Farhad Ravandi, Tapan M Kadia","doi":"10.1158/2643-3230.BCD-24-0171","DOIUrl":"10.1158/2643-3230.BCD-24-0171","url":null,"abstract":"<p><strong>Significance: </strong>In recent years, there has been tremendous interest surrounding the integration of venetoclax into both non-intensive and intensive chemotherapy regimens for AML. However, with this increasing utilization of venetoclax, considerable questions surrounding key issues such as dosing strategies and the practicality of venetoclax administration have arisen. This review highlights the evolution of venetoclax-based regimens in AML and provides a commentary on notable practical considerations when utilizing this agent.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"23-37"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total (Immuno)Therapy: Version 2.0. 全面（免疫）疗法》：2.0 版。
IF 11.5
Blood Cancer Discovery Pub Date : 2025-01-08 DOI: 10.1158/2643-3230.BCD-24-0236
Susan Bal, Luciano J Costa
{"title":"Total (Immuno)Therapy: Version 2.0.","authors":"Susan Bal, Luciano J Costa","doi":"10.1158/2643-3230.BCD-24-0236","DOIUrl":"10.1158/2643-3230.BCD-24-0236","url":null,"abstract":"<p><p>Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric antigen receptor T-cell therapy is now feasible. See related article by Fandrei et al., p. 38.</p>","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":" ","pages":"10-12"},"PeriodicalIF":11.5,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信